Literature DB >> 28196209

An Important Step Forward for Biosimilars in Cancer Treatment.

Stephen M Schleicher1, Andrew D Seidman2.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28196209     DOI： 10.1001/jamaoncol.2016.6789

Source DB:  PubMed          Journal:  JAMA Oncol        ISSN： 2374-2437            Impact factor:   31.777


× No keyword cloud information.
  1 in total

1.  Assessing Clinical Equivalence in Oncology Biosimilar Trials With Time-to-Event Outcomes.

Authors:  Hajime Uno; Deborah Schrag; Dae Hyun Kim; Dejun Tang; Lu Tian; Hope S Rugo; Lee-Jen Wei
Journal:  JNCI Cancer Spectr       Date:  2019-08-01
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.